| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | John A Chaddock | |
| Mark Elliott | |||
| Matthew Beard | |||
| Johannes Krupp | |||
| Elena Fonfria | |||
| P2860 | cites work | Two carbohydrate binding sites in the H(CC)-domain of tetanus neurotoxin are required for toxicity | Q44312023 |
| Botulinum neurotoxin A changes conformation upon binding to ganglioside GT1b | Q44993618 | ||
| Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates | Q45177751 | ||
| Molecular characterization of a novel botulinum neurotoxin type H gene | Q45290850 | ||
| THE NON-NEURONAL AND NON-MUSCULAR EFFECTS OF BOTULINUM TOXIN: A Graceful Opportunity for a Deadly Molecule to Treat a Human Disease in the Skin and Beyond. | Q45931052 | ||
| Recombinant Botulinum Toxoids: A Practical Guide for Production | Q46563949 | ||
| Substrate recognition strategy for botulinum neurotoxin serotype A. | Q46801352 | ||
| A 50-kDa fragment from the NH2-terminus of the heavy subunit of Clostridium botulinum type A neurotoxin forms channels in lipid vesicles | Q46983720 | ||
| Structural basis for the unique ganglioside and cell membrane recognition mechanism of botulinum neurotoxin DC. | Q47093993 | ||
| Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. | Q47776201 | ||
| Syntaxin and 25-kDa synaptosomal-associated protein: differential effects of botulinum neurotoxins C1 and A on neuronal survival | Q47956340 | ||
| Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. | Q48141244 | ||
| Botulinum neurotoxin type B. Its purification, radioiodination and interaction with rat-brain synaptosomal membranes | Q48385813 | ||
| Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity | Q48461901 | ||
| Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins | Q49164892 | ||
| Discovery of novel bacterial toxins by genomics and computational biology. | Q50040602 | ||
| Conserved structural features of the synaptic fusion complex: SNARE proteins reclassified as Q- and R-SNAREs | Q24656954 | ||
| Structural basis of cell surface receptor recognition by botulinum neurotoxin B | Q27643302 | ||
| Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity | Q27643303 | ||
| Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity | Q27647521 | ||
| Substrate Binding Mode and Its Implication on Drug Design for Botulinum Neurotoxin A | Q27652307 | ||
| Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A | Q27654586 | ||
| Glycosylated SV2 and Gangliosides as Dual Receptors for Botulinum Neurotoxin Serotype F | Q27655649 | ||
| Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F | Q27656103 | ||
| Gangliosides as High Affinity Receptors for Tetanus Neurotoxin | Q27656415 | ||
| Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner | Q27664044 | ||
| Identification of a Unique Ganglioside Binding Loop within Botulinum Neurotoxins C and D-SA, | Q27664131 | ||
| Structural analysis of the receptor binding domain of botulinum neurotoxin serotype D | Q27664616 | ||
| The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites | Q27667683 | ||
| Unique Ganglioside Recognition Strategies for Clostridial Neurotoxins | Q27671814 | ||
| Botulinum Neurotoxin Serotype C Associates with Dual Ganglioside Receptors to Facilitate Cell Entry | Q27673821 | ||
| Structures of engineeredClostridium botulinumneurotoxin derivatives | Q27675943 | ||
| Structure of dual receptor binding to botulinum neurotoxin B | Q27678834 | ||
| Identification of a novel botulinum neurotoxin gene cluster in Enterococcus | Q50091489 | ||
| Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium. | Q50207264 | ||
| Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons. | Q50865537 | ||
| Synaptotagmin-2, and -1, linked to neurotransmission impairment and vulnerability in Spinal Muscular Atrophy. | Q51148309 | ||
| Identification and Characterization of Botulinum Neurotoxin A Substrate Binding Pockets and Their Re-Engineering for Human SNAP-23. | Q51663202 | ||
| The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. | Q52312776 | ||
| Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA. | Q52567313 | ||
| Structural characterisation of the catalytic domain of botulinum neurotoxin X - high activity and unique substrate specificity. | Q52655358 | ||
| A lipid-binding loop of botulinum neurotoxin serotypes B, DC and G is an essential feature to confer their exquisite potency. | Q52803571 | ||
| Mechanism of substrate recognition by botulinum neurotoxin serotype A. | Q53575621 | ||
| Botulinum neurotoxin A and an engineered derivate targeted secretion inhibitor (TSI) A enter cells via different vesicular compartments. | Q54248975 | ||
| Targeted delivery of a SNARE protease to sensory neurons using a single chain antibody (scFv) against the extracellular domain of P2X(3) inhibits the release of a pain mediator. | Q54288877 | ||
| Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A. | Q54541506 | ||
| Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP-25 and Neurotoxicity after Reconstitution with the Heavy Chain | Q54599905 | ||
| The Expanding Therapeutic Utility of Botulinum Neurotoxins. | Q55105284 | ||
| Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25 | Q57979097 | ||
| Radioiodination of Botulinum Neurotoxin Type A with Retention of Biological Activity and Its Binding to Brain Synaptosomes | Q70245506 | ||
| Structural determinants of the specificity for synaptic vesicle-associated membrane protein/synaptobrevin of tetanus and botulinum type B and G neurotoxins | Q71246101 | ||
| Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle | Q71479210 | ||
| Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin | Q72715700 | ||
| A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro | Q73043502 | ||
| Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin | Q73120963 | ||
| The interaction of synaptic vesicle-associated membrane protein/synaptobrevin with botulinum neurotoxins D and F | Q73513535 | ||
| Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential | Q42452235 | ||
| Assembly of protein building blocks using a short synthetic peptide | Q42574076 | ||
| Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor | Q43299518 | ||
| Membrane Interaction of botulinum neurotoxin A translocation (T) domain. The belt region is a regulatory loop for membrane interaction. | Q43960895 | ||
| Crystal Structures of Botulinum Neurotoxin DC in Complex with Its Protein Receptors Synaptotagmin I and II | Q27679493 | ||
| Structure of a Bimodular Botulinum Neurotoxin Complex Provides Insights into Its Oral Toxicity | Q27680382 | ||
| Engineering Clostridia Neurotoxins with elevated catalytic activity | Q27685432 | ||
| Crystal structure of botulinum neurotoxin type A and implications for toxicity | Q27765727 | ||
| SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling | Q27860614 | ||
| History of Botulinum Toxin Treatment in Movement Disorders | Q28072264 | ||
| Synaptotagmin-2 is essential for survival and contributes to Ca2+ triggering of neurotransmitter release in central and neuromuscular synapses | Q28280944 | ||
| GHRH receptor-targeted botulinum neurotoxin selectively inhibits pulsatile GH secretion in male rats | Q28566580 | ||
| Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity | Q28572057 | ||
| Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage | Q28609220 | ||
| The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use. | Q30925493 | ||
| The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction | Q31036598 | ||
| Puzzling Out Synaptic Vesicle 2 Family Members Functions. | Q33710870 | ||
| Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. | Q33765582 | ||
| Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins | Q33793263 | ||
| Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors | Q33869062 | ||
| Tetanus and botulinum neurotoxins: turning bad guys into good by research | Q33998410 | ||
| SNARE tagging allows stepwise assembly of a multimodular medicinal toxin | Q34241315 | ||
| Cytotoxicity of botulinum neurotoxins reveals a direct role of syntaxin 1 and SNAP-25 in neuron survival | Q34327453 | ||
| What next for botulism vaccine development? | Q34343808 | ||
| Recombinant protein expression in Escherichia coli: advances and challenges | Q34421339 | ||
| Tetanus toxin entry. Nidogens are therapeutic targets for the prevention of tetanus | Q34449930 | ||
| Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System | Q34595178 | ||
| A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic | Q34675649 | ||
| Syntaxin requirement for Ca2+-triggered exocytosis in neurons and endocrine cells demonstrated with an engineered neurotoxin | Q34769128 | ||
| Families of metalloendopeptidases and their relationships | Q35489557 | ||
| Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons | Q35548169 | ||
| A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis | Q36190743 | ||
| Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells | Q36325534 | ||
| Generation and Characterization of Six Recombinant Botulinum Neurotoxins as Reference Material to Serve in an International Proficiency Test | Q36401425 | ||
| Synaptotagmin I is present mainly in autonomic and sensory neurons of the rat peripheral nervous system | Q36677907 | ||
| Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain | Q36891334 | ||
| Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin | Q36946982 | ||
| Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. | Q36992893 | ||
| Anti-ganglioside antibodies and the presynaptic motor nerve terminal | Q37196079 | ||
| Botulinum toxin for treatment of glandular hypersecretory disorders | Q37213533 | ||
| Engineering botulinum neurotoxin to extend therapeutic intervention. | Q37224285 | ||
| N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A. | Q37276819 | ||
| Cell entry strategy of clostridial neurotoxins | Q37490213 | ||
| Entry of a recombinant, full-length, atoxic tetanus neurotoxin into Neuro-2a cells | Q37546383 | ||
| Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature. | Q37641175 | ||
| Botulinum neurotoxin: a marvel of protein design | Q37710092 | ||
| Structures, biosynthesis, and functions of gangliosides--an overview | Q37936732 | ||
| Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering | Q37954285 | ||
| Clinical applications of botulinum toxin | Q38024438 | ||
| Engineered botulinum neurotoxins as new therapeutics | Q38135496 | ||
| Production of recombinant botulism antigens: a review of expression systems | Q38220327 | ||
| Botulinum neurotoxins: genetic, structural and mechanistic insights. | Q38224215 | ||
| Botulinum neurotoxins: new questions arising from structural biology. | Q38256719 | ||
| Protein engineering: a new frontier for biological therapeutics | Q38286271 | ||
| Glycans Confer Specificity to the Recognition of Ganglioside Receptors by Botulinum Neurotoxin A. | Q38289813 | ||
| Botulinum neurotoxin type G proteolyses the Ala81-Ala82 bond of rat synaptobrevin 2. | Q38308843 | ||
| Gangliosides: glycosphingolipids essential for normal neural development and function | Q38459051 | ||
| The long journey of botulinum neurotoxins into the synapse | Q38561450 | ||
| Botulinum toxin drugs: brief history and outlook | Q38631025 | ||
| Botulinum toxin: State of the art. | Q38668149 | ||
| Conjugate of an IgG Binding Domain with Botulinum Neurotoxin A Lacking the Acceptor Moiety Targets Its SNARE Protease into TrkA-Expressing Cells When Coupled to Anti-TrkA IgG or Fc-βNGF. | Q38704063 | ||
| The Botulinum Toxin as a Therapeutic Agent: Molecular Structure and Mechanism of Action in Motor and Sensory Systems. | Q38729354 | ||
| Stapling of the botulinum type A protease to growth factors and neuropeptides allows selective targeting of neuroendocrine cells | Q39157207 | ||
| A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain. | Q39157856 | ||
| Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology | Q39207459 | ||
| Vaccines against Botulism | Q40059125 | ||
| Mechanism of substrate recognition by the novel Botulinum Neurotoxin subtype F5. | Q40078527 | ||
| Nonparalytic botulinum molecules for the control of pain. | Q40113769 | ||
| Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics | Q40265659 | ||
| Substrate recognition mechanism of VAMP/synaptobrevin-cleaving clostridial neurotoxins | Q40422695 | ||
| Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors | Q40971832 | ||
| Identification and characterization of a novel botulinum neurotoxin. | Q41245604 | ||
| Multivalent Chromosomal Expression of the Clostridium botulinum Serotype A Neurotoxin Heavy-Chain Antigen and the Bacillus anthracis Protective Antigen in Lactobacillus acidophilus | Q41487678 | ||
| Botulinum neurotoxin type C protease induces apoptosis in differentiated human neuroblastoma cells. | Q41561905 | ||
| Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A. | Q41789006 | ||
| Synthetic self-assembling clostridial chimera for modulation of sensory functions | Q41876523 | ||
| Affinity biosensors using recombinant native membrane proteins displayed on exosomes: application to botulinum neurotoxin B receptor. | Q42108314 | ||
| Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems. | Q42370735 | ||
| The first non Clostridial botulinum-like toxin cleaves VAMP within the juxtamembrane domain | Q42408273 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | toxicology | Q7218 |
| enzyme | Q8047 | ||
| bacterial protein | Q64923821 | ||
| P304 | page(s) | 278 | |
| P577 | publication date | 2018-07-04 | |
| P1433 | published in | Toxins | Q15724569 |
| P1476 | title | Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity | |
| P478 | volume | 10 |
| Q91879193 | Botulinum Neurotoxin, an Example of Successful Translational Research |
| Q91815851 | Critical Analysis of Neuronal Cell and the Mouse Bioassay for Detection of Botulinum Neurotoxins |
| Q92444080 | New Engineered-Botulinum Toxins Inhibit the Release of Pain-Related Mediators |
| Q99591478 | Structural and Biochemical Characterization of Botulinum Neurotoxin Subtype B2 Binding to Its Receptors |
Search more.